Pramlintide

DEA Class; Rx

Common Brand Names; Symlin, SymlinPen 120, SymlinPen 60

Indicated for the treatment of type 1 diabetes mellitus in patients who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy.

Hypersensitivity

Gastroparesis

Hypoglycemia unawareness

Risk of severe insulin-induced hypoglycemia; pramlintide alone does not cause hypoglycemia; however, since it is indicated to be coadministered with mealtime insulin therapy, and in this setting there is an increased risk of severe hypoglycemia

Do not mix with insulin – administer the two separately

Slows gastric emptying, which may delay the absorption of concomitantly administered oral medications; administer the concomitant oral medication at least 1 hr prior or 2 hr after pramlintide

Slows gastric emptying; not recommended if taking other medications that alter gastrointestinal motility

Never share pen between patients even if needle is changed

Erythema, edema, or pruritus at site of injection reported; may be related to other factors, such as irritants in a skin cleansing agent or improper injection technique

Available data from a small number of reports in manufacturer’s safety database on use in pregnant women are not sufficient to determine a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes

There is no data on presence in human milk, effects on breastfed infant, or on milk production

Pramlintide Acetate

injectable solution

• 0.6mg/mL

pen-injector

• 15mcg/dose
• 30mcg/dose
• 45mcg/dose
• 60mcg/dose
• 120mcg/dose